Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT00143871
Phase
PHASE2
Status
Completed

Conditions

  • Lymphoma, Non-Hodgkin's

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is being conducted to determine the safety, side effects, and response to a combination of an established high-dose chemotherapy regimen, plus the addition of Rituximab (which is a form of immunotherapy).

Key Dates

First listed
Sep 2, 2005
Start date
Apr 30, 2001
Status verified
Jan 2012
Primary completion
Dec 31, 2006
Completion
Jan 31, 2007

Study Design

Enrollment
35 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Assess safety and toxicity after rituximab and high-dose chemotherapy

Locations (1)

FacilityCityStateZIPSite coordinators
The University of MichiganAnn ArborMichigan48109-

Find similar trials in Ann Arbor, MI

By research site
The University of Michigan· Ann Arbor, MI

Related Studies